Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2022

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated many options owing to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch and growing generics competition, the market is becoming increasingly crowded; meanwhile, early intervention with high-efficacy drugs continues to gain traction in lieu of treatment escalation, the prevailing paradigm. Thus, players engaged in or entering this space must assess where their products, especially next-in-class alternatives, will fit. This national patient-level claims data analysis explores treatment progression by line of therapy, persistence and compliance by brand, and the positioning of current DMTs.

Questions Answered

  • What patient shares do key brands and generics garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
  • How have competing S1P receptor modulators and anti-CD20 MAbs been integrated into the treatment algorithm, and what is their source of business? Is generic dimethyl fumarate having a discernible impact on prescribing patterns?
  • What percentage of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis.

Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan / Viatris, Novartis, Sanofi, Teva.

Key drugs covered: Aubagio, Bafiertam, Copaxone / glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia.

Key analysis provided:

  • Brand / therapy usage across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution Enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Login to access report

launch Related Market Assessment Reports